The Role of Ghrelin in Neuroprotection after Ischemic Brain Injury

Sarah J. Spencer 1,*, Alyson A. Miller 2 and Zane B. Andrews 3

1 School of Health Sciences and Health Innovations Research Institute (HIRi), RMIT University, Melbourne, VIC 3083, Australia
2 Department of Pharmacology, Faculty of Medicine, Monash University, Melbourne, VIC 3800, Australia; E-Mail: alyson.miller@monash.edu
3 Department of Physiology, Faculty of Medicine, Monash University, Melbourne, VIC 3800, Australia; E-Mail: zane.andrews@monash.edu

* Author to whom correspondence should be addressed; E-Mail: Sarah.Spencer@rmit.edu.au; Tel.: +61-3-9925-7745; Fax: +61-3-9925-6539.

Received: 10 December 2012; in revised form: 19 February 2013 / Accepted: 7 March 2013 / Published: 19 March 2013

Abstract: Ghrelin, a gastrointestinal peptide with a major role in regulating feeding and metabolism, has recently been investigated for its neuroprotective effects. In this review we discuss pre-clinical evidence suggesting ghrelin may be a useful therapeutic in protecting the brain against injury after ischemic stroke. Specifically, we will discuss evidence showing ghrelin administration can improve neuronal cell survival in animal models of focal cerebral ischemia, as well as rescue memory deficits. We will also discuss its proposed mechanisms of action, including anti-apoptotic and anti-inflammatory effects, and suggest ghrelin treatment may be a useful intervention after stroke in the clinic.

Keywords: ghrelin; neurodegeneration; apoptosis; inflammation

1. Introduction

The search for neuroprotective treatments after ischemic brain injury has so far proved remarkably unsuccessful. Indeed, recombinant tissue plasminogen activator (rt-PA), first introduced in the 1980s [1], is currently the only useful treatment for ischemic stroke. Although rt-PA effectively restores blood flow to the brain it cannot directly target the fundamental mechanisms of ischemic injury. Furthermore, owing to the narrow therapeutic window (less than 4.5 h), only a small proportion
of stroke patients actually receive rt-PA [2]. With ischemic stroke being the second leading cause of death and disability worldwide [3], there is a clear need for more effective therapies. As will be discussed below, emerging evidence suggests that ghrelin may be one such potential therapy.

Ghrelin is a 28 amino acid peptide that is principally synthesized in the gut, but is also expressed in a variety of other tissues [4,5]. It was first identified in 1999 as a stimulator of growth hormone release [5]. Ghrelin exists in the plasma in a des-acylated and an acylated form, the latter of which is the result of post-translational octanoylation of pro-ghrelin by the enzyme ghrelin-O-acyltransferase (GOAT) [6]. Acylated ghrelin is the natural ligand of the growth hormone secretagogue receptor type 1a (ghrelin receptor, GHS-R1a) through which growth hormone release is stimulated [5–7].

Since this initial description, research has attributed many other functions to the peptide, including its well-known role in feeding and metabolism [8–11]. Under situations of food deprivation, acylated ghrelin signals through the hypothalamus to promote feeding and energy conservation [10,12]. Ghrelin also has a number of significant extra-hypothalamic neuronal functions, including in reward and motivation [13,14], learning and memory [15], and stress [16,17]. For instance, we have recently shown ghrelin attenuates the hypothalamic-pituitary-adrenal axis response to acute stress, probably by acting on the anterior pituitary to stimulate adrenocorticotropic hormone release and thus enhance glucocorticoid negative feedback [16].

The GHS-R1a is expressed throughout the brain including in feeding and metabolism-associated areas like the arcuate nucleus (ARC) [18–20], as well as regions important in memory (Cornu Ammonis (CA)2, CA3, dentate gyrus of the hippocampus) and reward (ventral tegmental area, substantia nigra pars compacta (SNpc), dorsal raphe) [19,21,22]. The GHS-R1a is a g-protein coupled seven transmembrane receptor. Ghrelin activates the GHS-R1a leading to stimulation of the phospholipase C (PLC)/protein kinase C (PKC)/inositol trisphosphate (IP3) pathway that triggers IP3-dependent calcium release from intracellular stores. This intracellular calcium coupled with calcium entering the cell via voltage-gated L-type calcium channels stimulates the GHS-R1a’s downstream responses [23–25]. In addition to its ghrelin-dependent effects, the GHSR has high constitutive activity in the absence of the ligand [26]. It is also able to dimerize with other receptors such as the dopamine receptor subtype 2 to modulate dopamine signaling [27], and the melanocortin-3 receptor to modulate melanocortin signaling [28]. Ghrelin itself is also able to cross the blood brain barrier [5,18,29,30], making the ligand and receptor ideally placed to play an integral role in these diverse functions. As discussed below, evidence now suggests ghrelin may also have a role in neuroprotection in the setting of neurodegenerative disease and ischemic injury.

2. Ghrelin’s Role in Neuroprotection

2.1. Parkinson’s and Alzheimer’s Diseases

Evidence for a role for ghrelin in neuroprotection came initially from findings that the peptide is able to inhibit apoptosis in cardiomyocytes [31], and protect these cells from myocardial ischemia-reperfusion injury [32,33]. These findings have since been extended to a role for ghrelin in neuroprotection in Parkinson’s (PD) and Alzheimer’s (AD) diseases [34]. Thus, endogenous and exogenous ghrelin have been shown to protect dopamine neurons of the SNpc in a
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-induced mouse model of PD [35–37]. It also protects against dopamine depletion in the striatum [36]. In this PD model, ghrelin protects the brain by upregulating uncoupling protein 2 resulting in enhanced mitochondrial respiration and a reduction in reactive oxygen species production [36]. Ghrelin also reverses the pro-apoptotic effects of MPTP and enhances the firing rate of the dopamine neurons to enhance dopamine availability during degeneration [36]. Interestingly, recent evidence suggests ghrelin production may be reduced in PD patients [38], raising the possibility that a reduction in ghrelin-mediated neuroprotection may contribute to increased vulnerability of dopaminergic neurons.

With respect to AD, it is also noteworthy that plasma levels of ghrelin naturally decrease with age (in AD and in age-matched non-dementia subjects) [39] but AD is further associated with reduced brain GHS-R1a levels and reduced levels of brain GOAT [40]. Exogenous ghrelin is able to rescue memory deficits in mice given amyloid beta oligomers into the hippocampus. It also reduces the amyloid beta oligomer-induced microgliosis and neuronal loss in this region, and prevents amyloid beta oligomer-associated synaptic degeneration [41]. In vitro, ghrelin is able to limit tau hyperphosphorylation and increase glucose uptake in hippocampal neurons via a mechanism that involves the phosphatidylinositol 3-kinase (PI3K)/Akt/glycogen synthase kinase-3 beta (GSK-3B) pathway [42].

2.2. Cerebral Ischemia

2.2.1. Observations of Neuroprotection

It is also now evident that ghrelin can be a powerful neuroprotective agent in experimental models of cerebral ischemia. One of the first studies in this field revealed synthetic ghrelin (GHS-hexarelin) reduces injury to the cerebral cortex, hippocampus, and thalamus after neonatal hypoxia-ischemia [43]. As with AD, the neuroprotective effect here is associated with phosphorylation of Akt and GSK3B, indicating the PI3K pathway is involved.

Early studies using models of adult stroke examined the effects of exogenous ghrelin administered immediately after either forebrain or focal ischaemia-reperfusion injury. Thus, Liu and colleagues [44] found ghrelin given i.p. daily for three days after a transient ischemia-reperfusion injury (four vessel occlusion) in the rat significantly increased the number of surviving neurons in the CA1 region of the hippocampus and significantly decreased the number of TUNEL-positive neurons in this region. Exogenous ghrelin also improves neurological deficit, infarct size, and survival of cortical neurons in rodents after transient focal ischemia-reperfusion (middle cerebral artery occlusion; MCAO) [45,46]. Again, similar to in PD models, its mechanism of action appears to be inhibition of pro-apoptotic pathways [45,46]. These findings are crucial from a clinical perspective. As with PD and AD, ghrelin levels are reduced in clinical stroke populations. In particular, ghrelin levels have been reported to be lower in male patients after cardioembolic stroke compared with the healthy controls [47]. Given the apparent neuroprotective properties of ghrelin, restoring ghrelin levels after stroke is therefore likely to have significant beneficial outcomes. We also suggest measuring ghrelin levels after stroke could be used as a diagnostic tool to predict prognosis.
2.2.2. Mechanisms of Neuroprotection

There are three principal types of cell death induced by cerebral ischemia and hypoxic injury; apoptosis, necrosis, and autophagy [48]. In cases of focal ischemia, such as with an MCAO in rodents, or a focal stroke in humans, the major mechanism of cell death within the ischemic core is necrosis, and this occurs immediately after the insult [49]. The more delayed cell death that occurs in the ischemic penumbra (3–24 h and beyond) occurs via principally apoptotic and autophagic mechanisms [49], against which ghrelin may be useful. In cases of global cerebral ischemia, such as occurs in the brain after a cardiac arrest, the principal mechanism of cell death appears to be necrosis [50], and ghrelin may be less useful in these cases. However, we should note there is likely considerable overlap between these mechanisms of cell death.

Apoptosis is a mechanism of cell “suicide” that is regulated by specific signaling pathways and can occur by caspase-dependent and caspase-independent mechanisms [48]. Necrosis has been termed a “cellular catastrophe”, where the cell fails due to a deficiency of ATP. However, it now appears some necrotic events are a consequence of specific signaling pathways. Necroptosis is one example of a necrotic-type cell death process that is regulated by cell signaling [48,49]. Neuronal cell death after ischemia can also occur via autophagy (type II death); a cellular degradation process wherein the mitochondria remain intact and functional. Autophagy is a normal cellular process that is initially protective and can promote neuronal survival [51], but under extreme conditions degradation of macromolecules and organelles such as the Golgi apparatus, endoplasmic reticulum, and polyribosomes ensues [48].

2.2.2.1. Ghrelin Protects against Apoptosis

When a cell becomes sufficiently depleted of oxygen and nutrients, pro-apoptotic genes involved in cell death are activated. This activation leads to the stimulation of pro-apoptotic BAX and suppression of anti-apoptotic Bcl2. These proteins interact to regulate the permeability of the mitochondrial permeability transition pore [52–55]. When BAX is activated, cytochrome c is released from the mitochondria and interacts with Apaf-1 such that Apaf-1 forms a complex with pro-caspase 9, leading to activation of caspase-9 and -3. Mitochondrial dysfunction therefore plays an important role in cell survival. Evidence suggests ghrelin inhibits apoptotic mechanisms by activating the extracelluar-signalling-regulated-kinase (ERK)1/2, mitogen-activated protein kinase, protein kinase A, and protein kinase C pathways [36,56]. The activation of these pathways is associated with reduced activation of BAX, an improved Bcl2/BAX ratio and suppression of apoptosis/improved cell survival (Figure 1). Ghrelin also suppresses apoptosis by increasing expression of mitochondrial uncoupling protein UCP2. UCP2 elevation effectively buffers production of reactive oxygen species, protecting the cell from oxidative stress and reducing apoptosis [36,57,58]. Protective increases in UCP2 with ghrelin have been observed in traumatic brain injury and PD models [36,58].

In the MPTP model of PD, ghrelin reverses the reduced expression of Bcl2 and increased expression of BAX associated with the MPTP to improve the Bcl2/BAX ratio and prevent apoptosis [35]. Similarly, in the MCAO (focal) and four vessel occlusion (forebrain) models of ischemia reperfusion, ghrelin suppresses the increase in the pro-apoptotic gene, Par-4, associated with
the ischemia [44,59]. Ghrelin thus also improves the Bcl2/BAX ratio and inhibits cytochrome c release and caspase-3 activation [44,59]. The neuroprotective effects of ghrelin are also mediated by activation of PI3K/Akt. Stimulation of this pathway by ghrelin leads to phosphorylation and inactivation of GSK-3B and stabilization of beta-catenin [56,60]. Beta-catenin is then able to translocate to the nucleus and stimulate transcription of various cell survival factors [56].

**Figure 1.** Ghrelin inhibits apoptosis and protects against inflammation. Ghrelin stimulates extracellular-signalling-regulated-kinase (ERK)1/2, mitogen-activated protein kinase (MAPK), protein kinase A (PKA), and protein kinase C (PKC) pathways to reduce activation of BAX, improve the Bcl2/BAX ratio and thus suppress apoptosis and improve cell survival. Inset; ghrelin inhibits neutrophil, lymphocyte, and microglial activation to suppress pro-inflammatory cytokine production and the secretion of inflammatory neurotoxins.

This anti-apoptotic role for ghrelin is also seen after other neurodegenerative insults. Ghrelin ameliorates the reduction of pAkt and Bcl2 and attenuates the increase in caspase-3 expression in the caecal ligation and perforation model of sepsis. This action leads to a reduced cognitive deficit in this model [61]. Ghrelin also improves central outcomes after traumatic brain injury, suppressing caspase-3 expression and reducing cell death around the impact site [58]. *In vitro* studies also suggest an anti-apoptotic role for ghrelin, with ghrelin treatment of primary hypothalamic neurons inhibiting apoptosis after oxygen-glucose deprivation via rapid ERK1/2 activation [62].
2.2.2.2. Ghrelin’s Effects on Necrosis and Autophagy

To our knowledge, unlike with apoptosis, there is no current evidence that ghrelin directly influences necrotic neuronal cell death. Ghrelin may protect against necrosis caused by persistent ischemia in musculoskeletal tissues, but it does so by up-regulating iNOS, which, in turn, improves the local microcirculation [63]. There is some evidence ghrelin may be able to encourage cell survival by stimulating autophagy in cardiomyocytes under simulated hypoxic conditions leading to a more efficient removal of damaged organelles and misfolded proteins [64]. However, this pathway has not yet been examined in vivo or in models of cerebral ischemia. Also, care must be taken with the interpretation of these results as extensive autophagy can be detrimental to the cell [48].

2.2.2.3. Acylated versus Des-Acylated Ghrelin

It is interesting that ghrelin appears to be neuroprotective somewhat independently of acylation state [56]. Both ghrelin forms have been reported to prevent cell death and apoptosis in cultured neurons exposed to oxygen and glucose deprivation (an in vitro model of ischemia) [56,62], suggesting the neuroprotective actions of ghrelin in vivo are likely to occur through direct effects on neurons and independently of growth hormone release. Both acylated and des-acylated ghrelin also protect cortical neurons after transient focal ischemia-reperfusion (MCAO). In both cases, ghrelin can prevent apoptosis by suppressing the increase in expression of the pro-apoptotic gene Par-4 [56]. Acylated and des-acylated ghrelin also both improve the Bcl2/BAX ratio, and inhibit cytochrome c release and caspase-3 activation [59]. While it is clear the effects of acylated ghrelin are mediated by the GHS-R1a [56,59], des-acylated ghrelin does not activate GHS-R1a [34], and its neuroprotective effects are unaffected by the GHS-R1a antagonist D-Lys-3-growth hormone releasing peptide (GHRP)-6 [56]. The receptor through which des-acylated ghrelin mediates its neuroprotective effects remains to be determined. The GHS-R1a is certainly important for ghrelin’s neuroprotective actions, however. For example, in the MPTP model of PD, both ghrt−/− and GHSR−/− mice have greater loss of dopamine neurons in the SNpc than wild type mice [36]. Similarly, expression of the GHS-R1a is reduced in the brain [45] and spinal cord [65] by ischemia-reperfusion and exogenous ghrelin treatment is able to reverse this effect, leading to an improved Bcl2/BAX ratio [45]. Of potential importance, the GHS-R1a has considerable constitutive activity in the absence of the ligand [26] and may significantly contribute to limiting apoptosis after ischemia even when ghrelin is low.

2.2.2.4. Ghrelin Protects against Inflammation

In the hours to days after an ischemic event, the degree of inflammation plays a significant role in the severity of the injury [66]. In the early stages of ischemia-reperfusion, neutrophils and lymphocytes are recruited to the injury site and these are mostly neurotoxic, secreting inflammatory mediators such as cytokines and contributing to brain injury [67]. Microglia and astrocytes are then activated and secrete pro-inflammatory cytokines and other factors, such as inducible nitric oxide synthase (iNOS), that are also cytotoxic [68]; although microglia also play a protective role in removing cytotoxic debris at some stages of the inflammation [66,69].
Another mechanism by which ghrelin may improve cell survival after ischemia is therefore by suppressing inflammation (Figure 1). Exogenously applied ghrelin successfully suppresses inflammation in many models of pathology, including sepsis [70], non-alcoholic fatty liver disease [71], burn-induced multiple organ injury [72], traumatic brain injury [73], and ischemia [46]. For instance, after subarachnoid haemorrhage, ghrelin can suppress the release of the pro-inflammatory cytokines tumour necrosis factor (TNF)\(\alpha\) and interleukin (IL)-1\(\beta\) to improve outcomes [74]. Ghrelin suppresses TNF\(\alpha\) and IL-6 induced by traumatic brain injury [73]. Likewise, ghrelin reduces the serum TNF\(\alpha\) and myeloperoxidase activity induced by ischemic-reperfusion spinal cord injury [65].

Ghrelin’s neuroprotective role in PD is partially due to its anti-inflammatory effects. Thus, ghrelin is able to reduce MPTP-associated microglial activation in the SNcp and striatum as well as reduce the expression of TNF\(\alpha\), and IL-1\(\beta\) mRNA, and iNOS activation in the ventral midbrain to improve neuronal survival in these regions [37]. These anti-inflammatory effects are potentially GHS-R1a-mediated (i.e., due to acylated ghrelin and not des-acylated ghrelin) as the antagonist, D-Lys-3-GHRP-6, attenuates the effect [37].

Ghrelin also extends this anti-inflammatory function to cerebral ischemia-reperfusion injury. Ghrelin treatment in rats after an MCAO reduced MCAO-induced neutrophil trafficking, TNF\(\alpha\), IL-6, matrix metalloproteinase 9, and nNOS, as well as apoptosis [46]. This treatment was associated with reduced infarct size, reduced neurological deficit, and improved 7-day survival. In this case it appears ghrelin’s mechanism of action is at least partially vagally mediated, as prior vagotomy blunted this neuroprotective effect [46]. A role for the vagus has also been suggested for ghrelin’s action in traumatic brain injury [75]. Ghrelin, thus, may be useful as an anti-inflammatory agent in cases of neurodegenerative disease.

3. Clinical Considerations

Experimental evidence in animal models clearly suggests ghrelin may be a useful therapeutic after cerebral ischemia. This role may prove to be all the more crucial when we consider the ghrelin system appears to be altered in the setting of known stroke risk factors such as aging, obesity, and hypertension. For example, during the normal aging process there is a reduction in the sensitivity to the metabolic effects of ghrelin [76–78]. This insensitivity may be compounded by an aging-related decline in circulating ghrelin levels [39]. Obesity is associated with a central resistance to the metabolic effects of ghrelin [79], and ghrelin levels are reduced in obese and overweight humans [80]. Similarly, low ghrelin levels have also been reported to be independently associated with the development of type two diabetes and elevated blood pressure [81], and the Arg51Gln (rs34911341) single-nucleotide polymorphism of ghrelin is linked to an increased risk of hypertension, and is associated with low ghrelin levels [82]. Circulating ghrelin is also lower in patients who have experienced stroke than in the general population when controlling for factors such as age and obesity [47]. Collectively, these findings raise the intriguing possibility that low ghrelin levels per se may be a risk factor for stroke, and imply that ghrelin might not only be an effective intervention therapy after a stroke has occurred, but also an approach to prevent a stroke from occurring in the first place. There is therefore a strong rationale to evaluate whether increasing ghrelin levels and/or improving sensitivity to circulating ghrelin during aging is an effective strategy to prevent ischemic
stroke damage. Of importance, experimental evidence indicates ghrelin can influence the sensitivity of the brain to its actions [62,83]. Specifically, studies have shown that GHS-R1a expression in the brain is increased following either central or peripheral administration of ghrelin to rodents [62,83]. Thus, sensitivity to circulating ghrelin could be improved during stroke risk factors (and after stroke) by “simply” increasing circulating ghrelin levels through ghrelin supplementation.

An important consideration with using ghrelin as a therapeutic is the timing of the dose. As suggested, restoring normal ghrelin levels in aging or other populations where ghrelin is low may be a viable therapy, and in this case chronic ghrelin treatment would be necessary. An alternative strategy is to employ a single or repeated supra-physiological dose as a therapeutic agent and the vast majority of preclinical studies have tested single doses of exogenous ghrelin at the time of injury (Table 1). Unfortunately, this is likely to be effective only in the 30 min or so after administration, as ghrelin’s half-life is very short (approximately 25–30 min in humans [84,85]). As such, a single dose at this time would likely influence early apoptosis and inflammation, but not affect the ongoing ischemic injury. Since brain damage after ischemic injury can continue to worsen for hours to days and weeks after the event depending upon the type of injury [86], chronic ghrelin treatment may be more appropriate after injury as well as a prophylaxis. In either case, such treatments need to be considered carefully and further research is needed. For instance, studies have shown glutamatergic neurotransmission is necessary for ghrelin’s effects on mesolimbic dopaminergic reward pathways [87] and that ghrelin stimulates memory formation in a glutamate-dependent manner [15]. However, excessive glutamate release can lead to excitotoxicity [88], which would obviously be detrimental after ischemic injury. The circadian timing of the ghrelin administration must also be considered, as evidence from the PD model suggests exogenous ghrelin may only be effective if the subject is fasted [36].

When evaluating the overall usefulness of ghrelin as a therapeutic for cerebral injury after ischemia, it is also important to consider the potential long-term consequences on body homeostasis. For example, exogenous acylated ghrelin would be expected to act at the GHS-R1a to stimulate appetite, food intake, and weight gain. While this may be a problem in the general population, it may actually be of benefit in those recovering from stroke as weight loss after stroke has been linked with a worse long-term prognosis [89]. Thus, ghrelin as a stroke therapy could have an additional beneficial effect by preventing age-related malnutrition and frailty, as well as weight loss after stroke. An alternative option in those where weight gain is a concern is also to employ the des-acylated form of ghrelin. Des-acylated ghrelin does not act at GHS-R1a and does not have the same metabolic effects as the acylated form. It is, however, effective at preventing neurodegeneration and improving outcomes after ischemic damage [56]. Further research will be necessary to determine its mechanism of action and effects on other neuronal functions such as reward and stress, but treatment with des-acylated ghrelin is nonetheless a useful potential option.
Table 1. Effects, and associated mechanisms, of ghrelin on outcomes after cerebral ischemia. All studies were conducted in rats except where indicated. Arrows are relative to vehicle-treated ischemic groups.

| Ischemic injury                              | Dose                                      | Timing                                   | Effect                                      | Mechanism of action                           | Reference |
|----------------------------------------------|-------------------------------------------|------------------------------------------|---------------------------------------------|-----------------------------------------------|-----------|
| Oxygen-glucose deprivation in cultured cells | Acylated and unacylated ghrelin, 100 nM each | Pretreatment for 24 h                    | ↓ cell death (both)                         | ↓ apoptosis                                    | [56,62]   |
| Doxorubicin H9c2 cardiomyocytes              | Total ghrelin, 1 µM                        | Co-treatment for 24 h                    | ↓ cell death (both)                         | ↓ apoptosis GHSR-1a-independent mechanism     | [31]      |
| 4VO forebrain ischemia/reperfusion           | Total ghrelin, i.p., 0.4 mg/kg            | Daily for 3 days post injury             | ↑ cell survival CA1 hippocampus             | ↓ apoptosis                                    | [44]      |
| MCAO Focal ischemia/reperfusion              | Total ghrelin, i.v., 10 pmol/kg           | Immediately post injury                  | ↓ cortical neuron injury                     | ↓ apoposis                                     | [45]      |
| MCAO                                         | Total ghrelin, i.v., ~7 pmol/kg           | Immediately post injury; infusion for 1 h | ↓ neurological deficit, ↓ infarct size at 24 h and 7 days | ↓ apoposis ↓ inflammation                      | [46]      |
| MCAO                                         | Total (80 µg/kg) or desacyl (160 µg/kg), i.p. | 30 min prior to injury and immediately post | ↓ cortical neuron injury (both)            | ↓ apoposis GHSR-1a-independent mechanism     | [59]      |
| Neonatal hypoxia-ischemia                    | GHS-hexarelin, icv, 1 µg in 5 µL          | Immediately post injury                  | ↓ cortical, hippocampal, thalamic injury, ↔ striatum | ↓ apoptosis                                    | [43]      |
| Spinal cord ischemia/reperfusion             | Total ghrelin, i.p., 100 µg/kg            | Ischemia onset                           | ↑ neurological scores                       | ↓ apoposis ↓ inflammation ↑ expression of GHSR-1a | [65]      |
| Subarachnoid hemorrhage                      | Total ghrelin, i.p., 10 µg/kg/day         | Immediately post injury and 24 h later    | ↑ neurological scores                       | ↓ inflammation                                 | [74]      |
| Traumatic brain injury                       | Total ghrelin, i.v., 4, 8 or 16 nmol/rat  | 45 min post-injury                       | ↓ cortical neuron injury                    | ↓ apoposis ↓ inflammation                      | [73]      |
| Traumatic brain injury                       | Total ghrelin, i.p., 10 µg/kg/dose        | Immediately prior to and 1 h post injury  | ↓ cell death                                | ↓ inflammation ↓ blood brain barrier permeability | [58]      |
4. Conclusions

The research reviewed here suggests the peptide hormone, ghrelin, may be an exciting novel candidate in our search for treatments for ischemic brain injury. It is clear ghrelin treatment can provide significant neuroprotection in a number of models of neurodegenerative disease and following ischemic brain injury. Indeed, ghrelin is effective in improving cell survival, reducing infarct size and rescuing memory in these models. It does this primarily by suppressing the apoptosis and inflammation associated with the ischemic injury. However, it remains to be determined whether ghrelin also modulates necrotic or autophagic mechanisms of cell death. Nonetheless, these exciting data collectively point to ghrelin potentially being very useful in the clinic as a neuroprotective treatment.

References

1. Papadopoulos, S.M.; Chandler, W.F.; Salamat, M.S.; Topol, E.J.; Sackellares, J.C. Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke. J. Neurosurg. 1987, 67, 394–398.
2. Demers, G.; Meurer, W.J.; Shih, R.; Rosenbaum, S.; Vilke, G.M. Tissue Plasminogen Activator and Stroke: Review of the Literature for the Clinician. J. Emerg. Med. 2012, 43, 1149–1154.
3. World Health Organization (WHO). The top 10 causes of death. Available online: http://www.who.int/mediacentre/factsheets/fs310/en/index.html (accessed on 9 December 2012).
4. Lago, F.; Gonzalez-Juanatey, J.R.; Casanueva, F.F.; Gomez-Reino, J.; Dieguez, C.; Gualillo, O. Ghrelin, the same peptide for different functions: Player or bystander? Vitam. Horm. 2005, 71, 405–432.
5. Kojima, M.; Hosoda, H.; Date, Y.; Nakazato, M.; Matsuo, H.; Kangawa, K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402, 656–660.
6. Yang, J.; Brown, M.S.; Liang, G.; Grishin, N.V.; Goldstein, J.L. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 2008, 132, 387–396.
7. Gutierrez, J.A.; Solenberg, P.J.; Perkins, D.R.; Willency, J.A.; Knierman, M.D.; Jin, Z.; Witcher, D.R.; Luo, S.; Onyia, J.E.; Hale, J.E. Ghrelin octanoylation mediated by an orphan lipid transferase. Proc. Natl. Acad. Sci. USA 2008, 105, 6320–6325.
8. Cummings, D.E. Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol. Behav. 2006, 89, 71–84.
9. Tschop, M.; Smiley, D.L.; Heiman, M.L. Ghrelin induces adiposity in rodents. Nature 2000, 407, 908–913.
10. Cowley, M.A.; Smith, R.G.; Diano, S.; Tschop, M.; Pronchuk, N.; Grove, K.L.; Strasburger, C.J.; Bidlingmaier, M.; Esterman, M.; Heiman, M.L.; et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003, 37, 649–661.
11. Briggs, D.I.; Andrews, Z.B. Metabolic status regulates ghrelin function on energy homeostasis. Neuroendocrinology 2011, 93, 48–57.
12. Andrews, Z.B. Central mechanisms involved in the orexigenic actions of ghrelin. *Peptides* 2011, 32, 2248–2255.
13. Abizaid, A.; Liu, Z.W.; Andrews, Z.B.; Shanabrough, M.; Borok, E.; Elsworth, J.D.; Roth, R.H.; Sleeman, M.W.; Picciotto, M.R.; Tschop, M.H.; *et al.* Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. *J. Clin. Invest.* 2006, 116, 3229–3239.
14. Naleid, A.M.; Grace, M.K.; Cummings, D.E.; Levine, A.S. Ghrelin induces feeding in the mesolimbic reward pathway between the ventral tegmental area and the nucleus accumbens. *Peptides* 2005, 26, 2274–2279.
15. Diano, S.; Farr, S.A.; Benoit, S.C.; McNay, E.C.; da Silva, I.; Horvath, B.; Gaskin, F.S.; Nonaka, N.; Jaeger, L.B.; Banks, W.A.; *et al.* Ghrelin controls hippocampal spine synapse density and memory performance. *Nat. Neurosci.* 2006, 9, 381–388.
16. Spencer, S.J.; Xu, L.; Clarke, M.A.; Lemus, M.; Reichenbach, A.; Geenen, B.; Kozicz, T.; Andrews, Z.B. Ghrelin regulates the hypothalamic-pituitary-adrenal axis and restricts anxiety after acute stress. *Biol. Psychiatry* 2012, 72, 457–465.
17. Kojima, M.; Kangawa, K. Ghrelin: Structure and function. *Physiol. Rev.* 2005, 85, 495–522.
18. Howard, A.D.; Feighner, S.D.; Cully, D.F.; Arena, J.P.; Liberator, P.A.; Rosenblum, C.I.; Hamelin, M.; Hreniuk, D.L.; Palyha, O.C.; Anderson, J.; *et al.* A receptor in pituitary and hypothalamus that functions in growth hormone release. *Science* 1996, 273, 974–977.
19. McKeever, P.S.; Wollday, D.P.; Madsen, A.N.; Egerod, K.L.; Jin, C.; Lang, M.; Rasmussen, M.; Beck-Sickinger, A.G.; Holst, B. *In vivo* characterization of high Basal signaling from the ghrelin receptor. *Endocrinology* 2009, 150, 4920–4930.
27. Kern, A.; Albarran-Zeckler, R.; Walsh, H.E.; Smith, R.G. Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism. *Neuron* **2012**, *73*, 317–332.

28. Rediger, A.; Piechowski, C.L.; Yi, C.X.; Tarnow, P.; Strotmann, R.; Gruters, A.; Krude, H.; Schoneberg, T.; Tschop, M.H.; Kleinau, G.; Biehermann, H. Mutually opposite signal modulation by hypothalamic heterodimerization of ghrelin and melanocortin-3 receptors. *J. Biol. Chem.* **2011**, *286*, 39623–39631.

29. Banks, W.A.; Tschop, M.; Robinson, S.M.; Heiman, M.L. Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. *J. Pharmacol. Exp. Ther.* **2002**, *302*, 822–827.

30. Muccioli, G.; Tschop, M.; Papotti, M.; Deghenghi, R.; Heiman, M.; Ghigo, E. Neuroendocrine and peripheral activities of ghrelin: Implications in metabolism and obesity. *Eur. J. Pharmacol.* **2002**, *440*, 235–254.

31. Baldanzi, G.; Filigheddu, N.; Cutrupi, S.; Catapano, F.; Bonissoni, S.; Fubini, A.; Malan, D.; Baj, G.; Granata, R.; Broglio, F.; *et al.* Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. *J. Cell Biol.* **2002**, *159*, 1029–1037.

32. Chang, L.; Ren, Y.; Liu, X.; Li, W.G.; Yang, J.; Geng, B.; Weintraub, N.L.; Tang, C. Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart. *J. Cardiovasc. Pharmacol.* **2004**, *43*, 165–170.

33. Frascarelli, S.; Ghelardoni, S.; Ronca-Testoni, S.; Zucchi, R. Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart. *Basic Res. Cardiol.* **2003**, *98*, 401–405.

34. Andrews, Z.B. The extra-hypothalamic actions of ghrelin on neuronal function. *Trends Neurosci.* **2010**, *34*, 31–40.

35. Jiang, H.; Li, L.J.; Wang, J.; Xie, J.X. Ghrelin antagonizes MPTP-induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra. *Exp. Neurol.* **2008**, *212*, 532–537.

36. Andrews, Z.B.; Erion, D.; Beiler, R.; Liu, Z.W.; Abizaid, A.; Zigman, J.; Elsworth, J.D.; Savitt, J.M.; DiMarchi, R.; Tschop, M.; *et al.* Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism. *J. Neurosci.* **2009**, *29*, 14057–14065.

37. Moon, M.; Kim, H.G.; Hwang, L.; Seo, J.H.; Kim, S.; Hwang, S.; Lee, D.; Chung, H.; Oh, M.S.; Lee, K.T.; Park, S. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease by blocking microglial activation. *Neurotox. Res.* **2009**, *15*, 332–347.

38. Unger, M.M.; Moller, J.C.; Mankel, K.; Eggert, K.M.; Bohne, K.; Bodden, M.; Stiasny-Kolster, K.; Kann, P.H.; Mayer, G.; Tebbe, J.J.; Oertel, W.H. Postprandial ghrelin response is reduced in patients with Parkinson’s disease and idiopathic REM sleep behaviour disorder: A peripheral biomarker for early Parkinson’s disease? *J. Neurol.* **2011**, *258*, 982–990.

39. Proto, C.; Romualdi, D.; Cento, R.M.; Spada, R.S.; Di Mento, G.; Ferri, R.; Lanzone, A. Plasma levels of neuropeptides in Alzheimer’s disease. *Gynecol. Endocrinol.* **2006**, *22*, 213–218.
40. Gahete, M.D.; Rubio, A.; Cordoba-Chacon, J.; Gracia-Navarro, F.; Kineman, R.D.; Avila, J.; Luque, R.M.; Castano, J.P. Expression of the ghrelin and neurotensin systems is altered in the temporal lobe of Alzheimer’s disease patients. *J. Alzheimers Dis.* 2010, 22, 819–828.

41. Moon, M.; Choi, J.G.; Nam, D.W.; Hong, H.S.; Choi, Y.J.; Oh, M.S.; Mook-Jung, I. Ghrelin ameliorates cognitive dysfunction and neurodegeneration in intrahippocampal amyloid-beta1-42 oligomer-injected mice. *J. Alzheimers Dis.* 2011, 23, 147–159.

42. Chen, Y.; Cao, C.P.; Li, C.R.; Wang, W.; Han, L.L.; Zhang, X.Q.; Kim, A.; Kim, S.; Liu, G.L. Ghrelin modulates insulin sensitivity and tau phosphorylation in high glucose-induced hippocampal neurons. *Biol. Pharm. Bull.* 2010, 33, 1165–1169.

43. Brywe, K.G.; Leverin, A.L.; Gustavsson, M.; Mallard, C.; Granata, R.; Destefanis, S.; Volante, M.; Hagberg, H.; Ghigo, E.; Isgaard, J. Growth hormone-releasing peptide hexarelin reduces neonatal brain injury and alters Akt/glycogen synthase kinase-3beta phosphorylation. *Endocrinology* 2005, 146, 4665–4672.

44. Liu, Y.; Wang, P.S.; Xie, D.; Liu, K.; Chen, L. Ghrelin reduces injury of hippocampal neurons in a rat model of cerebral ischemia/reperfusion. *Chin. J. Physiol.* 2006, 49, 244–250.

45. Miao, Y.; Xia, Q.; Hou, Z.; Zheng, Y.; Pan, H.; Zhu, S. Ghrelin protects cortical neuron against focal ischemia/reperfusion in rats. *Biochem. Biophys. Res. Commun.* 2007, 359, 795–800.

46. Cheyuo, C.; Wu, R.; Zhou, M.; Jacob, A.; Coppa, G.; Wang, P. Ghrelin suppresses inflammation and neuronal nitric oxide synthase in focal cerebral ischemia via the vagus nerve. *Shock* 2011, 35, 258–265.

47. Kantorova, E.; Chomova, M.; Kurca, E.; Sivak, S.; Zelenak, K.; Kucera, P.; Galajda, P. Leptin, adiponectin and ghrelin, new potential mediators of ischemic stroke. *Neuro Endocrinol. Lett.* 2011, 32, 716–721.

48. Xu, M.; Zhang, H.L. Death and survival of neuronal and astrocytic cells in ischemic brain injury: A role of autophagy. *Acta Pharmacol. Sin.* 2011, 32, 1089–1099.

49. Broughton, B.R.; Reutens, D.C.; Sobey, C.G. Apoptotic mechanisms after cerebral ischemia. *Stroke* 2009, 40, e331–e339.

50. Colbourne, F.; Auer, R.N. Transient Global Cerebral Ischemia Produces Morphologically Necrotic, Not Apoptotic Neurons. In *Acute Neuronal Injury: The Role of Excitotoxic Programmed Cell Death Mechanisms*; Fujikawa, D.G., Ed.; Springer Science + Business Media: Berlin, Germany, 2010.

51. Carloni, S.; Buonocore, G.; Balduini, W. Protective role of autophagy in neonatal hypoxia-ischemia induced brain injury. *Neurobiol. Dis.* 2008, 32, 329–339.

52. Culmsee, C.; Zhu, Y.; Kriegstein, J.; Mattson, M.P. Evidence for the involvement of Par-4 in ischemic neuron cell death. *J. Cereb. Blood Flow Metab.* 2001, 21, 334–343.

53. Shi, Y. A structural view of mitochondria-mediated apoptosis. *Nat. Struct. Biol.* 2001, 8, 394–401.

54. Yoshida, H.; Kong, Y.Y.; Yoshida, R.; Elia, A.J.; Hakem, A.; Hakem, R.; Penninger, J.M.; Mak, T.W. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. *Cell* 1998, 94, 739–750.
55. Offen, D.; Beart, P.M.; Cheung, N.S.; Pascoe, C.J.; Hochman, A.; Gorodin, S.; Melamed, E.; Bernard, R.; Bernard, O. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 5789–5794.

56. Chung, H.; Seo, S.; Moon, M.; Park, S. Phosphatidylinositol-3-kinase/Akt/glycogen synthase kinase-3 beta and ERK1/2 pathways mediate protective effects of acylated and unacylated ghrelin against oxygen-glucose deprivation-induced apoptosis in primary rat cortical neuronal cells. *J. Endocrinol.* **2008**, *198*, 511–521.

57. Andrews, Z.B.; Liu, Z.W.; Wallingford, N.; Erion, D.M.; Borok, E.; Friedman, J.M.; Tschop, M.H.; Shanabrough, M.; Cline, G.; Shulman, G.I.; *et al*. UCP2 mediates ghrelin’s action on NPY/AgRP neurons by lowering free radicals. *Nature* **2008**, *454*, 846–851.

58. Lopez, N.E.; Gaston, L.; Lopez, K.R.; Coimbra, R.C.; Hageny, A.; Putnam, J.; Eliceiri, B.; Coimbra, R.; Bansal, V. Early ghrelin treatment attenuates disruption of the blood brain barrier and apoptosis after traumatic brain injury through a UCP-2 mechanism. *Brain Res.* **2012**, *1489*, 140–148.

59. Hwang, S.; Moon, M.; Kim, S.; Hwang, L.; Ahn, K.J.; Park, S. Neuroprotective effect of ghrelin is associated with decreased expression of prostate apoptosis response-4. *Endocrine J.* **2009**, *56*, 609–617.

60. Chung, H.; Chung, H.Y.; Bae, C.W.; Kim, C.J.; Park, S. Ghrelin suppresses tunicamycin- or thapsigargin-triggered endoplasmic reticulum stress-mediated apoptosis in primary cultured rat cortical neuronal cells. *Endocrine J.* **2011**, *58*, 409–420.

61. Wang, G.; Wang, W.; Zhao, J.; Ni, Y.; Zhou, X.; Zhang, W. Ghrelin prevents neuronal apoptosis and cognitive impairments in sepsis-associated encephalopathy. *Neuroreport* **2011**, *22*, 959–964.

62. Chung, H.; Kim, E.; Lee, D.H.; Seo, S.; Ju, S.; Lee, D.; Kim, H.; Park, S. Ghrelin inhibits apoptosis in hypothalamic neuronal cells during oxygen-glucose deprivation. *Endocrinology* **2007**, *148*, 148–159.

63. Rezaeian, F.; Wettstein, R.; Scheuer, C.; Baumker, K.; Bachle, A.; Vollmar, B.; Menger, M.D.; Harder, Y. Ghrelin protects musculocutaneous tissue from ischemic necrosis by improving microvascular perfusion. *Am. J. Physiol. Heart Circ. Physiol.* **2012**, *302*, H603–H610.

64. Tong, X.X.; Wu, D.; Wang, X.; Chen, H.L.; Chen, J.X.; Wang, X.X.; Wang, X.L.; Gan, L.; Guo, Z.Y.; Shi, G.X.; *et al*. Ghrelin protects against cobalt chloride-induced hypoxic injury in cardiac H9c2 cells by inhibiting oxidative stress and inducing autophagy. *Peptides* **2012**, *38*, 217–337.

65. Zhang, Q.; Huang, C.; Meng, B.; Tang, T.; Shi, Q.; Yang, H. Acute effect of ghrelin on ischemia/reperfusion injury in the rat spinal cord. *Int. J. Mol. Sci.* **2012**, *13*, 9864–9876.

66. Wang, Q.; Tang, X.N.; Yenari, M.A. The inflammatory response in stroke. *J. Neuroimmunol.* **2007**, *184*, 53–68.

67. Hallenbeck, J.M. Significance of the inflammatory response in brain ischemia. *Acta Neurochir.* *Suppl.* **1996**, *66*, 27–31.

68. Wood, P.L. Microglia as a unique cellular target in the treatment of stroke: Potential neurotoxic mediators produced by activated microglia. *Neuro. Res.* **1995**, *17*, 242–248.
69. Watanabe, H.; Abe, H.; Takeuchi, S.; Tanaka, R. Protective effect of microglial conditioning medium on neuronal damage induced by glutamate. *Neurosci. Lett.* **2000**, *289*, 53–56.

70. Wu, R.; Dong, W.; Zhou, M.; Cui, X.; Hank Simms, H.; Wang, P. Ghrelin improves tissue perfusion in severe sepsis via downregulation of endothelin-1. *Cardiovasc. Res.* **2005**, *68*, 318–326.

71. Li, Y.; Hai, J.; Li, L.; Chen, X.; Peng, H.; Cao, M.; Zhang, Q. Administration of ghrelin improves inflammation, oxidative stress, and apoptosis during and after non-alcoholic fatty liver disease development. *Endocrine* **2012**, doi:10.1007/s12020-012-9761-5.

72. Sehirli, O.; Sener, E.; Sener, G.; Cetinel, S.; Erzik, C.; Yegen, B.C. Ghrelin improves burn-induced multiple organ injury by depressing neutrophil infiltration and the release of pro-inflammatory cytokines. *Peptides* **2008**, *29*, 1231–1240.

73. Qi, L.; Cui, X.; Dong, W.; Barrera, R.; Nicastro, J.; Coppa, G.F.; Wang, P.; Wu, R. Ghrelin attenuates brain injury after traumatic brain injury and uncontrolled hemorrhagic shock in rats. *Mol. Med.* **2012**, *18*, 186–193.

74. Bansal, V.; Ryu, S.Y.; Lopez, N.; Allexan, S.; Krzyzaniak, M.; Eliceiri, B.; Baird, A.; Coimbra, R. Vagal stimulation modulates inflammation through a ghrelin mediated mechanism in traumatic brain injury. *Inflammation* **2012**, *35*, 214–220.

75. Broglio, F.; Benso, A.; Castiglioni, C.; Gottero, C.; Prodam, F.; Destefanis, S.; Gauna, C.; van der Lely, A.J.; Deghenghi, R.; Bo, M.; *et al.* The endocrine response to ghrelin as a function of gender in humans in young and elderly subjects. *J. Clin. Endocrinol. Metab.* **2003**, *88*, 1537–1542.

76. Briggs, D.I.; Enriori, P.J.; Lemus, M.B.; Cowley, M.A.; Andrews, Z.B. Diet-induced obesity causes ghrelin resistance in arcuate NPY/AgRP neurons. *Endocrinology* **2010**, *151*, 4745–4755.

77. Tschop, M.; Weyer, C.; Tataranni, P.A.; Devanarayan, V.; Ravussin, E.; Heiman, M.L. Circulating ghrelin levels are decreased in human obesity. *Diabetes* **2001**, *50*, 707–709.

78. Poykko, S.M.; Kellokoski, E.; Horkko, S.; Kauma, H.; Kesaniemi, Y.A.; Ukkola, O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. *Diabetes* **2003**, *52*, 2546–2553.

79. Poykko, S.; Ukkola, O.; Kauma, H.; Savolainen, M.J.; Kesaniemi, Y.A. Ghrelin Arg51Gln mutation is a risk factor for Type 2 diabetes and hypertension in a random sample of middle-aged subjects. *Diabetologia* **2003**, *46*, 455–458.
83. Nogueiras, R.; Tovar, S.; Mitchell, S.E.; Rayner, D.V.; Archer, Z.A.; Dieguez, C.; Williams, L.M. Regulation of growth hormone secretagogue receptor gene expression in the arcuate nuclei of the rat by leptin and ghrelin. *Diabetes* **2004**, *53*, 2552–2558.

84. Akamizu, T.; Kangawa, K. Translational research on the clinical applications of ghrelin. *Endocrine J.* **2006**, *53*, 585–591.

85. Vestergaard, E.T.; Hansen, T.K.; Gormsen, L.C.; Jakobsen, P.; Moller, N.; Christiansen, J.S.; Jorgensen, J.O. Constant intravenous ghrelin infusion in healthy young men: Clinical pharmacokinetics and metabolic effects. *Am. J. Physiol. Endocrinol. Metab.* **2007**, *292*, E1829–E1836.

86. Lipton, P. Ischemic cell death in brain neurons. *Physiol. Rev.* **1999**, *79*, 1431–1568.

87. Jerlhag, E.; Egecioglu, E.; Dickson, S.L.; Engel, J.A. Glutamatergic regulation of ghrelin-induced activation of the mesolimbic dopamine system. *Addict. Biol.* **2011**, *16*, 82–91.

88. Meldrum, B.S. Glutamate as a neurotransmitter in the brain: Review of physiology and pathology. *J. Nutr.* **2000**, *130*, 1007S–1015S.

89. Scherbakov, N.; Dirnagl, U.; Doehner, W. Body weight after stroke: Lessons from the obesity paradox. *Stroke* **2011**, *42*, 3646–3650.

© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).